- Lipitor may be the first statin to switch to OTC
- Senate passes Drug Quality and Security Act
- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- 21 health industry groups address FDA on proposed changes to generic drug label rules
- Q&A: Genetic profiling with Dr. Anita Goel of Nanobiosym
NEW YORK — The Food and Drug Administration has approved a new cancer drug made by Pfizer, the drug maker said.
The FDA approved Pfizer's Xalkori (crizotinib) capsules, a treatment for patients with non-small cell lung cancer that has advanced locally or spread to other parts of the body, also known as metastasis. The drug specifically is designed to target NSCLC containing the enzyme anaplastic lymphoma kinase, as determined by a companion test also approved by the FDA.
"Overall, lung cancer is responsible for more deaths each year worldwide than any other type of cancer," Pfizer president and CEO Ian Read said. "Xalkori is an advance in the treatment of this devastating illness, providing a new therapeutic option for a subset of patients with the disease."